New Research Reverses Long-Held Beliefs on Overactive Bladder Medications and Dementia Risk
Commonly prescribed medications for overactive bladder do not carry a greater long-term risk of dementia than newer drug classes previously assumed to be safer for the brain. The findings emerged from a study published on November 6 in JAMA Network Open, challenging years of clinical assumptions regarding anticholinergic drugs and cognitive decline.
Researchers at University Hospitals Cleveland Medical Center Urology Institute examined health records for 830,393 adults aged 40 to 90 who started treatment for overactive bladder between 2012 and 2025. The large-scale analysis utilized the Epic Cosmos electronic health record database to track dementia rates across different medication classes.
How Older and Newer Bladder Drugs Compare in Dementia Rates
For years, physicians considered beta-3 agonists to be a safer choice for older adults because older anticholinergic drugs like oxybutynin carried a feared link to cognitive impairment. However, the new data reveals that dementia rates remained similar across both medication classes. The group of higher-risk anticholinergics—which includes oxybutynin, tolterodine, and solifenacin—yielded a hazard ratio of 0.90 compared to beta-3 agonists. Oxybutynin alone showed a hazard ratio of 0.92, indicating that the older medications were tied to slightly lower dementia rates rather than elevated risks.
Study authors noted that this slight variance likely reflects patient selection factors rather than a protective biological effect from the older drugs. Because the investigation compared two active treatment groups and excluded patients taking no medication, it cannot establish a total absence of risk. Short-term cognitive side effects can still occur with anticholinergics in a minority of patients, though these symptoms typically resolve once treatment stops.
Why Overactive Bladder May Serve as an Early Warning Sign
The study points to an alternative explanation for the observed association between bladder issues and cognitive decline. Rather than medications causing dementia, researchers suggest that overactive bladder and the underlying neurologic mechanisms leading to urinary incontinence may act as early warning signs of neurodegenerative processes.
Lead author David Sheyn, a urogynecologist at University Hospitals Cleveland Medical Center Urology Institute, explained that the underlying pathology of dementia often begins decades before formal symptoms appear. This timeline explains why previous observational studies, which typically tracked patients for five years or less, flagged bladder drugs as the culprit.
Clinical Implications and Next Steps for Patients
Healthcare providers can reassure patients that a short trial of anticholinergic medication does not cause cognitive harm. If patients experience substantial symptom relief, they can safely continue their regimen. Even so, clinical guidelines will not change immediately. Dr. Sheyn emphasized that these results require independent reproduction before medical societies rewrite official prescribing recommendations, leaving beta-3 agonists as the preferred initial choice whenever feasible.
Frequently Asked Questions About Bladder Meds and Cognitive Health
Did the study prove that bladder medications are completely safe for the brain?
No, the study compared patients taking different medications and did not include an untreated control group, meaning it cannot prove the drugs carry zero risk. It only demonstrates that anticholinergics do not pose a higher dementia risk than beta-3 agonists.
What should patients do if they experience memory issues while taking an anticholinergic drug?
While short-term cognitive side effects affect a minority of users, these symptoms typically resolve entirely once the medication is stopped.
Worth a look